In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the world’s largest non-profit funder of neuroendocrine cancer research. Since 2005, NETRF has awarded $40 million across 76 institutions in 17 countries. Dr. Greene emphasized the urgent need for increased funding and researcher engagement, outlining NETRF’s four grant categories that fuel innovative, high-impact studies.
She also detailed NETRF’s comprehensive patient support efforts, including trusted educational resources and the NETWise podcast. Looking ahead, NETRF is guided by a new research roadmap focused on early detection, improved treatments, and precision medicine. Dr. Greene expressed excitement about recent clinical trials stemming from NETRF-funded research, including a CAR T-cell immunotherapy and a novel uPAR-targeted approach for patients with high-grade NETs.
As federal research funding faces uncertainty, Greene called for greater awareness and investment to ensure continued progress in this underfunded cancer field.
Watch the interview below or read the interview transcript.